These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 348306)

  • 41. Patient case involving high-dose methotrexate followed by leucovorin rescue.
    Alsop JA
    Am J Hosp Pharm; 1978 Feb; 35(2):127. PubMed ID: 305201
    [No Abstract]   [Full Text] [Related]  

  • 42. New "rescue" with massive doses of citrovorum factor for potentially lethal methotrexate toxicity.
    Djerassi I; Kim JS; Nayak N; Ohanissian H; Adler S; Hsieh S
    Cancer Treat Rep; 1977 Jul; 61(4):749-50. PubMed ID: 301784
    [No Abstract]   [Full Text] [Related]  

  • 43. Hexamethylmelamine, vincristine, and methotrexate chemotherapy in advanced neoplasms.
    Longacre D; Donavan M; Paladine W; Cunningham T; Sponzo R
    Cancer Treat Rep; 1977 Aug; 61(5):919-22. PubMed ID: 408004
    [No Abstract]   [Full Text] [Related]  

  • 44. Phase II evaluation of metoprine with leucovorin rescue in patients with advanced colorectal carcinoma.
    Lynch G; Currie V; Kemeny N
    Cancer Clin Trials; 1981; 4(3):281-3. PubMed ID: 6974612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose methotrexate with leucovorin rescue.
    Akahoshi M
    Cancer Nurs; 1978 Aug; 1(4):319-25. PubMed ID: 307982
    [No Abstract]   [Full Text] [Related]  

  • 46. [Effects of a massive dosage of methotrexate and leucovorin rescue therapy on acute leukemia and malignant lymphoma].
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):421-32. PubMed ID: 6764106
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer.
    Yap HY; Benjamin RS; Blumenschein GR; Hortobagyi GN; Tashima CK; Buzdar AU; Bodey GP
    Cancer Treat Rep; 1979 Jan; 63(1):77-83. PubMed ID: 369695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical and pharmacological studies of methotrexate-minimal leucovorin rescue plus fluorouracil.
    Wiemann MC; Cummings FJ; Kaplan HG; Spremulli EN; Doolittle CH; Calabresi P
    Cancer Res; 1982 Sep; 42(9):3896-900. PubMed ID: 6980707
    [No Abstract]   [Full Text] [Related]  

  • 49. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis.
    Hanrahan PS; Russell AS
    J Rheumatol; 1988 Jul; 15(7):1078-80. PubMed ID: 3050087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Methotrexate therapy of head and neck cancer: improvement in therapeutic index by the use of leucovorin "rescue".
    Capizzi RL; DeConti RC; Marsh JC; Bertino JR
    Cancer Res; 1970 Jun; 30(6):1782-8. PubMed ID: 4248129
    [No Abstract]   [Full Text] [Related]  

  • 51. [The influence of liver and renal functions on the changes in serum methotrexate (MTX) level in high-dose MTX therapy].
    Sato T; Nakanishi K; Takahashi M; Sato K; Miura T; Kuzuya T; Mizuno M
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2375-9. PubMed ID: 2260874
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Methotrexate. II. Use in pediatric chemotherapy.
    Lippens RJ
    Am J Pediatr Hematol Oncol; 1984; 6(4):397-413. PubMed ID: 6398630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Radiational basis and practice of the citrovorum factor (Leucovorin) protection after high-dose methotrexate therapy. High-dose methotrexate/leucovorin].
    Sauer H; Schalhorn A
    Onkologie; 1980 Apr; 3(2):64-71. PubMed ID: 6994007
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Methotrexate-leucovorin rescue therapy: pharmacological characteristics and clinical effective use].
    Fujimoto T
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1901-6. PubMed ID: 8978794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low dose methotrexate with leucovorin rescue in AS.
    Ferraz MB; da Silva HC; Atra E
    J Rheumatol; 1991 Jan; 18(1):146-7. PubMed ID: 2023187
    [No Abstract]   [Full Text] [Related]  

  • 56. High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma.
    Dimitrov NV; Egner J; Balcueva E; Suhrland LG
    Cancer; 1982 Oct; 50(7):1245-7. PubMed ID: 6980698
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.
    Samuels LL; Straw JA
    Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
    Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
    Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of mitomycin C, cyclophosphamide, and methotrexate in drug-resistant colorectal carcinoma.
    Presant CA; Ratkin G; Klahr C
    Cancer Treat Rep; 1978 Apr; 62(4):549-50. PubMed ID: 350389
    [No Abstract]   [Full Text] [Related]  

  • 60. High dose intravenous methotrexate for refractory rheumatoid arthritis.
    Shiroky JB; Neville C; Skelton JD
    J Rheumatol; 1992 Feb; 19(2):247-51. PubMed ID: 1629823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.